Eli Lilly delivered a blowout Q1 earnings beat driven by soaring GLP-1 sales, raising full-year guidance by $2 billion as CNBC, BioPharma Dive, and pharmaphorum reported. Elsewhere, Avalyn Pharma priced an upsized $300M IPO for its pulmonary fibrosis program, while AstraZeneca announced resumed U.K. R&D expansion following favorable U.S.-UK trade terms. Clinical trial activity accelerated with new Phase III studies in ovarian cancer and triple-negative breast cancer now recruiting patients.
Top Stories
Lilly Posts Blowout Q1 on GLP-1 Momentum, Raises 2026 Outlook by $2B
Eli Lilly reported quarterly results that blew past analyst estimates, driven by skyrocketing sales of Zepbound and Mounjaro, with particularly strong international performance from Mounjaro, according to CNBC and BioPharma Dive. The company raised full-year sales guidance by $2 billion and lifted adjusted profit expectations, though investors are eager for more details on the commercial rollout of oral weight-loss drug Foundayo, with CNBC reporting more than 20,000 patients are now taking the pill. pharmaphorum noted management remained reticent on detailed Foundayo launch metrics during the quarterly update. This signals Lilly's GLP-1 franchise remains the industry's most powerful growth engine, though the cautious Foundayo messaging suggests the company is managing expectations carefully in a competitive oral obesity market.
Avalyn Pharma Prices Upsized $300M IPO for Pulmonary Fibrosis Program
Boston-based Avalyn Pharma priced an upsized initial public offering at $18 per share, selling over 16.5 million shares to raise approximately $300 million, as reported by Endpoints News and pharmaphorum. The company, which is developing therapies for pulmonary fibrosis, is set to begin trading Thursday under the ticker symbol AVLN on the Nasdaq. The successful pricing suggests continued investor appetite for respiratory-focused biotechs despite broader market volatility.
AstraZeneca Resumes U.K. R&D Expansion Following U.S. Trade Deal
AstraZeneca announced it will resume expansion of its U.K. research and development operations after a new U.S.-UK trade agreement included measures to lift U.K. pharmaceutical spending, Fierce Biotech and STAT reported. The move reverses previous uncertainty around the company's British investment plans and reflects how trade policy is increasingly shaping multinational biopharma capital allocation. This signals that diplomatic resolution of pricing disputes can unlock significant R&D investment, potentially setting a precedent for other markets.
Daiichi Sankyo and Merck Launch Phase III Trials in TNBC and Ovarian Cancer
Two major Phase III antibody-drug conjugate trials began recruiting patients, according to ClinicalTrials.gov: Daiichi Sankyo's dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in PD-L1 positive locally recurrent or metastatic triple-negative breast cancer, and Merck's sacituzumab tirumotecan (MK-2870) maintenance treatment versus standard of care in platinum-sensitive recurrent ovarian cancer (NCT06824467). Both studies represent significant late-stage investments in ADC platforms for difficult-to-treat gynecologic and breast malignancies. Worth watching because these trials could establish new maintenance standards in settings with high unmet need.
XTL Biopharmaceuticals Acquires Psychedelic-Focused Psyga Bio
XTL Biopharmaceuticals announced it is acquiring 100% of outstanding shares of psychedelic biotech Psyga Bio, gaining access to Psyga's manufacturing facility and psychedelic development programs, Endpoints News reported. The deal marks continued consolidation in the nascent psychedelic therapeutics space as earlier entrants seek scale and infrastructure. The move suggests XTL sees value in owning dedicated manufacturing capacity for controlled substances as regulatory pathways clarify.
Bristol Myers Faces $14B Eliquis Patent Cliff Over Six Years
Bristol Myers Squibb and partner Pfizer are confronting projected revenue losses of $14 billion over six years beginning with the Eliquis loss of exclusivity in 2026, positioning it as one of the most consequential patent cliffs in pharmaceutical history, Pharmaceutical Technology reported. The anticoagulant's exclusivity erosion will test both companies' pipeline depth and their ability to offset massive revenue declines through business development. This signals heightened M&A pressure for Bristol Myers in particular, given its concentration of maturing assets.
What to Watch
- Foundayo Launch Metrics — Lilly's reticence on detailed oral GLP-1 rollout data suggests the company is managing market expectations carefully; clarity on prescriber adoption, payer coverage, and competitive positioning against Novo Nordisk's oral Wegovy will be critical in coming quarters.
- ADC Maintenance Strategies — Both the Merck ovarian cancer and Daiichi Sankyo TNBC trials test antibody-drug conjugates in maintenance settings, a potentially paradigm-shifting application if successful that could expand ADC use beyond active disease treatment.
- U.S.-UK Trade Precedent — AstraZeneca's resumed U.K. investment following trade negotiations could encourage other jurisdictions to seek similar bilateral agreements, potentially reshaping how governments negotiate pharmaceutical pricing and R&D investment commitments.
- Psychedelic Manufacturing Consolidation — XTL's acquisition of Psyga's manufacturing assets suggests dedicated controlled-substance production capacity is becoming a strategic differentiator as psychedelic programs advance toward commercialization.
Market Snapshot
- GLP-1 Dominance Continues: Lilly's $2 billion guidance raise driven by Mounjaro and Zepbound underscores the obesity and diabetes franchise remains the pharmaceutical industry's primary growth driver, with international expansion now contributing materially alongside U.S. demand.
- Biotech IPO Window Remains Open: Avalyn's successful $300M pricing at $18 per share, representing an upsized offering, indicates selective investor appetite for well-positioned clinical-stage assets persists despite broader market uncertainty.
- Patent Cliff Pressures Intensify: The $14 billion Eliquis erosion over six years exemplifies the scale of exclusivity challenges facing major pharma, with Bristol Myers and Pfizer needing significant pipeline or M&A activity to offset losses from single blockbuster LOEs.